Related Experiment Videos
Treatment of respiratory infections with fosfomycin
Abstract:
Results are presented for a series of 29 patients, 14 males and 15 females, with serious respiratory infections, in which fosfomycin proved effective. In all cases the study was completed by bacteriological, clinical, radiological and analytical controls. The average dose was 6 g/day (3 g orally and 3 g intramuscularly) for 1 or 2 weeks. The four isolated were P. aeruginosa, E. coli, Klebsiella-Enterobacter and D. pneumoniae. Overall sensitivity percentages were best for fosfomycin, gentamicin and colistin. Of the 29 germs isolated, only one strain of P. aeruginosa became resistant: this represents 3% resistance development. No side effects of intolerance or signs of hepatorenal insufficiency were observed during the treatment. Of the 29 patients treated, 22 were clinically cured, denoting 76% success.
Insights
Fosfomycin effectively treated serious respiratory infections in 29 patients, showing high sensitivity and a 76% cure rate with no significant side effects. This study highlights fosfomycin as a viable antibiotic option.
Area of Science:
- Infectious Diseases
- Pharmacology
- Respiratory Medicine
Background:
- Serious respiratory infections pose a significant clinical challenge.
- Evaluating antibiotic efficacy and safety is crucial for patient management.
Purpose of the Study:
- To assess the effectiveness and safety of fosfomycin in treating serious respiratory infections.
- To determine the sensitivity of common respiratory pathogens to fosfomycin and other antibiotics.
Main Methods:
- A series of 29 patients (14 males, 15 females) with serious respiratory infections were treated.
- Treatment involved an average dose of 6 g/day (oral and intramuscular) for 1-2 weeks.
- Bacteriological, clinical, radiological, and analytical controls were performed throughout the study.
Main Results:
- Fosfomycin demonstrated high overall sensitivity against isolated pathogens, including P. aeruginosa, E. coli, Klebsiella-Enterobacter, and D. pneumoniae.
- Only one strain of P. aeruginosa (3%) developed resistance during treatment.
- A 76% clinical cure rate (22 out of 29 patients) was observed, with no reported side effects or hepatorenal insufficiency.
Conclusions:
- Fosfomycin is an effective and well-tolerated antibiotic for treating serious respiratory infections.
- Low resistance development and high cure rates support fosfomycin's clinical utility.
- Fosfomycin, gentamicin, and colistin showed the best sensitivity percentages against the studied pathogens.